Malignant fungating wounds: epidemiology, aetiology, presentation and assessment These wounds can be devastating for patients and challenging for practitioners.
This article, the first in a series, examines the research literature on their aetiology and presentation, and suggests how they might be most effectively assessed incidence; malodour; quality of life; patient's perspective M alignant wounds are a devastating complication of cancer that usually signify advanced and incurable disease, with limited therapeutic options and a grave prognosis. They occur infrequently but are always distressing for patients, caregivers and nurses as they struggle to cope with the challenges associated with malodour, heavy exudate, pain, disfigurement and social isolation.
Although the literature on the management of malignant wounds is steadily increasing, much of it is fragmented and is mostly based on case studies, anecdotal reporting and expert opinion. As a result, there are no comprehensive formal guidelines or robust evidence on which to base practice.
The series will summarise the available literature in a holistic format that practitioners can use to inform their practice decisions. The first paper will focus on the epidemiology, aetiology, presentation and assessment of malignant wounds. The second paper will consider living with a malignant wound and psychological issues. The series will conclude with the management of malignant wounds.
Terminology
Terms used to describe malignant wounds include 'fungating wounds' and 'malignant cutaneous lesions'. Strictly speaking, 'fungating' refers to the appearance of the wound, and not all malignant wounds are fungating. The term 'malignant cutaneous lesions' can be misleading as it can refer to regions of the skin that have altered but not yet developed into wounds.
As the focus of this paper is on wounds that have developed as a result of cancerous processes, the term 'malignant wound' is used.
Literature review
A literature search was conducted of 11 databases using the search terms 'fungating' and 'malignant Subsequently, the reference lists of the identified articles were hand searched. This search was extended to before 1990, although less than 5% of the reviewed articles were pre-1990. Only English-language papers were reviewed.
In total, 264 journal articles, nine book chapters and one thesis were reviewed.
State of the evidence
The vast majority of the reviewed literature comprised anecdotal reporting and case studies or incorporated interventions from other disciplines. [1] [2] [3] [4] [5] [6] [7] Advice given on managing malignant wounds was often prescriptive, sometimes generalised from chronic wound management and frequently not based on empirical evidence. There was limited discussion of the psychosocial issues. A few articles gave an insight into what it might be like to live with a malignant wound but, until recently, there have been few systematic attempts to present the experience from the patient's perspective. Clearly, more robust research is needed.
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Only three randomised controlled trials (RCTs) investigated the management of malignant wounds, 11-13 but they were either underpowered, had methodological limitations or did not provide sufficient information to verify their results. 10, 14 They will be discussed later in this series.
Epidemiology
There are no exact statistics on the occurrence of malignant wounds as their incidence is not recorded 10 and the statistics that are available are often based on samples generated using different inclusion criteria. Most estimates vary from 5% to 10% of cancer patients.
The first systematic review of the frequency of cutaneous involvement reported a rate of 5%. The researchers retrospectively reviewed the records of a Pennsylvanian medical centre over a 10-year period and found 367 instances in 7,316 cases of cancer (3,839 metastatic) . 15 This review recorded all instances of metastatic cutaneous involvement (intact or non-intact skin) but did not include melanomas.
In a later analysis of the same data, the researchers reported a frequency of cutaneous involvement in 420 (10.4%) of 4,020 patients with metastatic disease -double the previous rate. 16 This apparent increase occurred because it was calculated as a percentage of metastatic cancers, including melanomas.
Neither study reported the proportion of intact versus non-intact cutaneous involvement.
Alvarez et al. reported a prevalence rate of almost 7% for malignant wounds in cancer patients at Calvary Hospital, US, but did not provide any details of the criteria used for this calculation. 17 Another study cited an incidence rate of 5.3% (including intact cutaneous lesions but excluding melanomas). 18 Accordingly, it seems reasonable to predict that over 5% of cancer patients will experience a malignant wound. As cancer treatments improve and human longevity increases, this statistic will no doubt increase.
A drawback of not knowing the incidence rate of malignant wounds is that it can be difficult to interest dressing manufacturers in developing new products if a sufficient market cannot be demonstrated. 19 The incidence of malignant wounds in children is extremely rare. 20 In their retrospective study of 4,020 cancer patients, Lookingbill et al. found only two cases of malignant wounds in children. 16 Most authors suggested that the prognosis for patients with malignant wounds was grave and that life expectancy may be less than six months. 21 Reports of individuals living for many years with malignant wounds were exceptional. 22, 23 After reviewing 77 cases of cutaneous tumour metastases over 10 years, Saeed et al. reported that 28.6% of patients had died within the first month following diagnosis, 66.23% had died within the first six months and 75% had died within the first 12 months. 23 Other researchers reported even worse survival rates. For example, Wu et al. claimed a mean survival of only six weeks following presentation of cutaneous metastases arising from genitourinary primary cancers, while Fyrmpas et al. reported that most patients with primaries in the lung, cervix or oesophagus died within three months of the appearance of cutaneous metastases. 24, 25 For patients with multiple sites of involvement, the prognosis was even worse as their average survival reduced by 30% compared with patients with single-site cutaneous metastasis. 23 Reports of malignant wounds healing are extremely rare. 26 Lund-Nielsen et al. reported success in healing a malignant wound but did not provide details. 27 Petrek et al. reported that three out of 19 breast malignant wounds healed following radiotherapy but did not provide any further details; the wound sizes ranged from 1cm to 8cm. 28 Lo et al. presented the case of a healed malignant breast lesion, but it was more superficial (6 x 7 x 1cm, width x length x depth ) than many of those discussed in the literature. 29 In any event, even if improvement or healing can be achieved, recurrence is common.
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Aetiology When a diagnosis of terminal cancer is exacerbated by the development of a malignant wound, the effect on quality of life can be devastating. In most cases, the wounds are caused by:
• Tumour cells metastasising from local or distant primary tumours • Primary cutaneous tumours • Direct invasion of a primary tumour into the cutaneous structure. 31 Other, less frequent causes have also been reported. For example, malignant wounds may occur in chronic wounds with a long duration (Marjolin's ulcer). 32 The possibility of malignant wounds arising as a result of tumour cells being implanted iatrogenically during surgical procedures such as mastectomy also has been discussed. 8, [33] [34] [35] Three studies reported on the development of skin metastases in scars from previous tumour excisions or other invasive procedures. 23, 36, 37 As cancer treatments improve survival rates, one complication might be an increased incidence of cutaneous malignancies arising from radiotherapy treatment for previous malignancies. 38 
Presentation
Malignant wounds may present as either a crater-like ulcer (destructive process) or raised nodules similar in appearance to a cauliflower (proliferating). This is why the term 'fungating' is sometimes used to describe proliferating wounds. 39 Wounds may also present as both ulcerating and proliferating. Carville differentiated between the two terms as follows:
'Fungating lesions are products of cancerous infiltration of the epithelium, resulting in a protruding nodular and often grotesque growth which is prone to infection, bleeding and malodorous exudate' The first sign of skin involvement is often the development of discrete, non-tender skin nodules resulting from tumour proliferation within the skin structure. Cutaneous metastasis may also present as erythematous plaques or areas of alopecia. 40 These abnormalities may eventually combine and develop into a malignant wound. As the cancerous processes advance, they disrupt blood and lymph vessels, causing a disorganised microcirculation, coagulopathy, buildup of waste, oedema, hypoxia and necrosis. 32, 41 Malignant wounds can grow rapidly, often enlarging noticeably within 24 hours, 42 and have the potential to cause massive skin damage. 2 Malignant wounds have been reported in locations as diverse as the nail bed, eyelid, scrotum and ear.
8, 23 Although every malignant tumour has the potential to metastasise to any body site, 43 some malignancies have a predilection for certain sites. Breast tumours metastasising to the breast or chest wall are the most common occurrence in women (39-62%), 44 while cutaneous metastases from primary lung cancers are the most frequent occurrence in men. 45 Other common sites include the head and neck (24-33.8%); back, trunk or abdomen (1-3%) ; groin or axilla (3-7%); and genitals (3-5%). 44 Patients with abdominal or perineal wounds may also develop sinuses or fistulae with internal body cavities, 41 which will exacerbate problems with malodour and exudate as faecal or other body substances may leak through the wound.
Assessment
Comprehensive assessment is particularly important in the context of complex disorders, such as malignant wounds, which are unique in every presentation, always difficult to treat, often incorporate a variety of problems and are capable of impacting dramatically on the quality of life of the patient and those caring for them. 32, 40, 41, 46 The assessment should be ongoing and incorporate all domains of the patient's illness experience (not just the wound), how they are coping with it and the ongoing impact on their own life and that of their family. It should include their nutritional status, ability to self-care, psychosocial issues (depression, body image, sexuality), past health history, current morbidities, allergies, social support, strengths and coping abilities, spiritual and cultural needs. 32, 47, 48 Open and effective communication will facilitate the patient's involvement in the planning and implementation of their care. 47 The importance of comprehensive, individual assessments was highlighted by Laverty, who report-ed on long-held assumptions that had subsequently been proven false. 46 She discussed the tendency of some practitioners to assume they knew what patients were experiencing because they thought that every patient dealt with symptoms in the same way. As the author pointed out, we may know what is happening to a patient but we will not know how they perceive these experiences unless we take time to understand the meaning for each individual patient.
Laverty's discussion reinforced the wisdom of assessing each patient as an individual -a 'clean slate' each time -in order to ensure a more accurate picture of the person and the impact of the disorder on their existence, their 'being-in-the-world'. In this way, by temporarily stepping into the patient's world and 'fusing horizons', the practitioner is better placed to gain an insight into the illness experience and its effects on the patient's life. 43 Acknowledging that the patient's priorities might be different to those of the practitioner, and adapting treatment accordingly, is an important component of patient-centred care.
An effective method of determining how the wound is affecting the patient is to invite them to self-assess the wound. Two tools have been developed for this purpose:
• The wound and symptoms self-asessment chart (WoSSAc) -a quantitative tool that identifies and rates the patient's symptoms and assesses the impact of the wound on the patient and their wider psychosocial environment. 49 Care should be exercised when interpreting the results as this is a standardised tool comprising pre-determined criteria and so may not capture the individual nature of the experience of living with a malignant wound. Further discussions with the patient may be necessary to fully comprehend their assessment of the wound and the meaning it has for them • Treatment evaluation by Le Roux's method (TEL-ER) combines descriptive techniques with quantitative measurements. It enables identification of individual needs, which inform the development of appropriate management plans. 50 By working together in this way, a joint assessment that incorporates the perspectives of both the patient and practitioner will facilitate the development of a truly patient-centred treatment plan.
Other researchers have highlighted the difficulties involved in assessing malignant wounds because of their complexity and uniqueness, and the rapidity with which they might change. 51, 52 Bearing these comments in mind, I have developed the malignant wound assessment guide outlined in Table 1 .
As malodour is such a prominent and distressing symptom of malignant wounds, 22, 53, 54 its assessment requires careful attention. 55 However, malodour is difficult to assess objectively in clinical practice. Its assessment is thus usually subjective, which can lead to wide variations. 57 Some authors have suggested that the patient's subjective assessment is the best indicator for nursing interventions. 42, 57 Others stated this is inadvisable as patients may become densensitised to smells over time. 58, 59 This topic of desensitisation has not been studied in any depth, but several authors have reported that patients with malignant wounds have remained acutely aware of their malodour. West described a patient with anal cancer who was 'fully aware of his malodour and frequently apologised for the smell'. 55 Van Toller stated that 'a person coming into the presence of putrescine and cadaverine will not become "unaware" of the smell and the malodour will persist and be constantly detectable'. 60 The results of a study involving 47 patients showed that patients are likely to remain aware of the malodour, whereas some practitioners assumed they became used to and unaware of it. 61 The investigators suggested that patients sometimes report lower scores because admitting to the intensity of the malodour also meant acknowledging the seriousness of their condition.
In my own experience, patients and their caregivers have reported that they remain acutely aware of the malodour and continuously adapted their way of life to avoid inflicting it on others.
Malodour is obviously an extremely sensitive topic that should be explored carefully and compassionately with the patient before making decisions on interventions.
In my own practice, I have used the malodour assessment guide developed by Haughton and Young (Table 2) . 62 When comparing my assessment with that of the patient, they have generally either matched my assessment of the malodour or assessed it as stronger than I have.
Conclusion
Malignant wounds represent a distressing additional burden to patients facing a terminal prognosis. The wounds can have a devastating impact, not only on the quality of the patient's remaining life, but also on his or her family. These wounds present an enormous challenge to practitioners, who often struggle to cope with the malodour, exudate and associated psychosocial issues.
There has been little formal research on malignant wounds, which has limited the availability of robust evidence on which to base management guidelines. Comprehensive and individualised assessment will ensure that treatment plans are patient-centred and take account of the patient's experience of the malignant wound and its effects on their life. Assessment of malodour is particularly important in this regard. ■ 
Strong
Odour is evident on entering the room (2-3 metres from the patient) when the dressing is intact
Moderate
Odour is evident on entering the room (2-3 metres from the patient) when the dressing is removed
Slight
Odour is evident at close proximity to the patient when the dressing is removed
No odour
No odour is evident, even at the patient's bedside, when the dressing is removed
